GC Cell Corporation (KOSDAQ:144510)
24,350
-1,050 (-4.13%)
At close: Feb 6, 2026
GC Cell Revenue
GC Cell had revenue of 45.02B KRW in the quarter ending September 30, 2025, a decrease of -0.73%. This brings the company's revenue in the last twelve months to 170.13B, down -7.72% year-over-year. In the year 2024, GC Cell had annual revenue of 174.45B, down -6.98%.
Revenue (ttm)
170.13B
Revenue Growth
-7.72%
P/S Ratio
2.15
Revenue / Employee
243.74M
Employees
698
Market Cap
365.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.45B | -13.09B | -6.98% |
| Dec 31, 2023 | 187.54B | -48.58B | -20.57% |
| Dec 31, 2022 | 236.12B | 67.81B | 40.29% |
| Dec 31, 2021 | 168.31B | 82.75B | 96.71% |
| Dec 31, 2020 | 85.56B | 27.67B | 47.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 89.78B |
| ISU Abxis | 66.39B |
| NIBEC | 32.96B |
| Genome & Company | 25.95B |
| S.Biomedics | 16.96B |
| Prestige Biologics | 13.36B |
| Y-Biologics | 3.61B |
| Vaxcell-Bio Therapeutics | 1.90B |